Elevated TSH concentrations associated with advanced hepatic fibrosis, even in euthyroid state
Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease suggests a recent study published in the BMC GastroenterologyObservational studies showed that low thyroid function may perturb liver function. We aimed to evaluate the association of low thyroid function with both metabolic...
Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease suggests a recent study published in the BMC Gastroenterology
Observational studies showed that low thyroid function may perturb liver function. We aimed to evaluate the association of low thyroid function with both metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced hepatic fibrosis.
Results
• A total of 19,946 participants were included, among which 14,789 were strict-normal thyroid function, 4,328 were low-normal thyroid function, 829 were subclinical hypothyroidism.
• TSH levels were significantly higher in MAFLD patients with a FIB-4 > 2.67 and /or NFS > 0.676 than their counterparts.
• The logistic regression model adjusted for age and sex showed that low-normal thyroid function increased the risk of MAFLD
• Multivariable regression model adjusted for age, sex, body mass index, type 2 diabetes, and hypertension showed low-normal thyroid function increased the risk of advanced fibrosis in patients with MAFLD
• Elevated TSH concentrations are associated with advanced hepatic fibrosis, even in the euthyroid state.
TAKE-HOME MESSAGE
This study assessed the association of hypoglycemia with concomitant use of sulfonylureas and beta-blockers versus sulfonylureas alone in patients with type 2 diabetes. Overall, the risk of hypoglycemia was higher in patients on both medications than in those on sulfonylureas alone even when adjusted for relative comorbidities such as heart failure and liver cirrhosis.
Patients may be at a higher risk for hypoglycemia with the use of beta-blockers in combination with sulfonylureas.
For further reference:
.Liu, Z. et al. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease. BMC Gastroenterol 23, 3 (2023). https://doi.org/10.1186/s12876-022-02612-3
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd